RT Journal Article
SR Electronic
T1 Effect of the <em>Mdr1a</em> P-Glycoprotein Gene Disruption on the Tissue Distribution of SDZ PSC 833, a Multidrug Resistance-Reversing Agent, in Mice
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 438
OP 443
VO 285
IS 2
A1 Desrayaud, S.
A1 De Lange, E. C. M.
A1 Lemaire, M.
A1 Bruelisauer, A.
A1 De Boer, A. G.
A1 Breimer, D. D.
YR 1998
UL http://jpet.aspetjournals.org/content/285/2/438.abstract
AB The involvement of mdr1a P-glycoprotein (P-gP) on the tissue distribution of the multidrug resistance-reversing agent SDZ PSC 833 was assessed by use of mdr1a (–/–) mice. Themdr1a (–/–) and wild-type mdr1a (+/+) mice received a 4-h constant-rate i.v. infusion (2 μg/min) of [14C]SDZ PSC 833. Mice were sacrificed at 0, 0.5, 1, 2 and 4 h during infusion and at 0.5, 1, 3, 8 and 24 h after stopping the infusion. Blood and tissues were analyzed on total (14C) and parental SDZ PSC 833 concentrations.Mdr1a (–/–) mice exhibited increased SDZ PSC 833 accumulation in cerebrum, cerebellum and somewhat in testes and small intestine compared with the wild-type mice. The difference betweenmdr1a (–/–) and (+/+) brain (cerebrum and cerebellum) penetration depended on SDZ PSC 833 blood concentrations, because this cyclosporin analog apparently governs its own brain penetration by inhibiting the P-glycoprotein pump in mdr1a (+/+) mice. Thus the mdr1a (–/–)/(+/+) ratio of brain concentrations tended to decrease and increase at high and low blood concentrations, respectively. These findings clearly demonstrate the interaction of SDZ PSC 833 with the P-glycoprotein present at the blood-brain barrier. The SDZ PSC 833 distribution in othermdr1a P-glycoprotein-expressed tissues, as well as its metabolism and elimination, was not affected by themdr1a gene disruption. This suggests that factors other than mdr1a P-gP are involved in the disposition of this multidrug resistance-reversing agent. The American Society for Pharmacology and Experimental Therapeutics